Valcyte
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Valganciclovir (Valcyte) |
| Overview | |
| FDA Approval | Yes (for CMV infections) |
| Used for | Investigational use in glioblastoma due to potential effects against CMV positive tumors |
| Clinical Trial Phase | Investigational, including early clinical trials |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Includes diarrhea, nausea, neutropenia, potential for increased risk of birth defects |
| OS without | Median survival with standard treatment: 17.4 months |
| OS with | Post-hoc analysis with at least six months of Valcyte use: median survival of 24 months, 4-year survival of 27% |
| PFS without | Not specified |
| PFS with | Not directly specified; improvements noted in selected patient analyses |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Valganciclovir, an anti-CMV drug, has been explored for glioblastoma treatment due to the majority of these tumors being positive for CMV proteins. Initial studies suggest a possible therapeutic benefit, especially with long-term use, but results require further validation through rigorously designed clinical trials to conclusively determine efficacy and optimal usage in glioblastoma treatment.
From Ben Williams Book: Not specified
Loading comments...
